CS1-Directed Monoclonal Antibody Therapy for Multiple Myeloma

被引：19
作者：
Benson, Don M., Jr. [1 ]
Byrd, John C. [1 ]
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 16期
关键词：
NATURAL-KILLER-CELL; LENALIDOMIDE PLUS DEXAMETHASONE; DOSE DEXAMETHASONE; CD2; SUBSET; 2B4; CD244; CYTOTOXICITY; CS1; BORTEZOMIB; CRACC; PROLIFERATION;
D O I：
10.1200/JCO.2011.40.4061
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：2013 / 2015
页数：3
相关论文
共 33 条
[1]  
Balasa B, 2008, BLOOD, P112
[2]   IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect [J].
Benson, Don M., Jr. ;
Bakan, Courtney E. ;
Zhang, Shuhong ;
Collins, Shauna M. ;
Liang, Jing ;
Srivastava, Shivani ;
Hofmeister, Craig C. ;
Efebera, Yvonne ;
Andre, Pascale ;
Romagne, Francois ;
Blery, Mathieu ;
Bonnafous, Cecile ;
Zhang, Jianying ;
Clever, David ;
Caligiuri, Michael A. ;
Farag, Sherif S. .
BLOOD, 2011, 118 (24) :6387-6391
[3]   2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes [J].
Boles, KS ;
Stepp, SE ;
Bennett, M ;
Kumar, V ;
Mathew, PA .
IMMUNOLOGICAL REVIEWS, 2001, 181 :234-249
[4]   Molecular cloning of CS1, a navel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily [J].
Boles, KS ;
Mathew, PA .
IMMUNOGENETICS, 2001, 52 (3-4) :302-307
[5]  
Borset M, 2000, BLOOD, V96, P2528
[6]   Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].
Cartron, G ;
Dacheux, L ;
Salles, G ;
Solal-Celigny, P ;
Bardos, P ;
Colombat, P ;
Watier, H .
BLOOD, 2002, 99 (03) :754-758
[7]  
Collins SM, 2011, J CLIN ONCOL S, V29, p183s
[8]   Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function [J].
Cruz-Munoz, Mario-Ernesto ;
Dong, Zhongjun ;
Shi, Xiaochu ;
Zhang, Shaohua ;
Veillette, Andre .
NATURE IMMUNOLOGY, 2009, 10 (03) :297-305
[9]   Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].
Davies, FE ;
Raje, N ;
Hideshima, T ;
Lentzsch, S ;
Young, G ;
Tai, YT ;
Lin, B ;
Podar, K ;
Gupta, D ;
Chauhan, D ;
Treon, SP ;
Richardson, PG ;
Schlossman, RL ;
Morgan, GJ ;
Muller, GW ;
Stirling, DI ;
Anderson, KC .
BLOOD, 2001, 98 (01) :210-216
[10]   Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [J].
Dimopoulos, Meletios ;
Spencer, Andrew ;
Attal, Michael ;
Prince, H. Miles ;
Harousseau, Jean-Luc ;
Dmoszynska, Anna ;
San Miguel, Jesus ;
Hellmann, Andrzej ;
Facon, Thierry ;
Foa, Robin ;
Corso, Alessandro ;
Masliak, Zvenyslava ;
Olesnyckyj, Marta ;
Yu, Zhinuan ;
Patin, John ;
Zeldis, Jerome B. ;
Knight, Robert D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2123-2132
1234